New study aims to uncover hidden liver risks in diabetes patients
NCT ID NCT07437157
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will follow 1,000 adults in Hong Kong who have both type 2 diabetes and a common fatty liver condition called MASLD. Researchers will collect health data and blood samples over time to see how the liver disease progresses and to find early markers of serious liver scarring. The goal is to better understand the link between diabetes and liver disease and improve future monitoring and care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could identify early warning signs and biomarkers that help predict who will develop severe liver damage, pointing toward better monitoring and prevention strategies.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to other populations. The findings will need further validation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Medicine and Therapeutics, The Chinese University of Hong Kong (CUHK), Ward 3M, Diabetes and Endocrine Research Centre, 3/F Day Treatment Block and Children Wards (Old Block), Prince of Wales Hospital
RECRUITINGHong Kong, New Territories, 99977, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••